Cue Biopharma (CUE) Assets Average (2018 - 2025)
Cue Biopharma (CUE) posted Assets Average of $36.9 million for Q4 2025, up 2.08% sequentially from $36.2 million in Q3 2025, and down 4.08% YoY from $38.5 million in Q4 2024.
Cue Biopharma (CUE) Assets Average (2018 - 2025) Analysis & Trends
Cue Biopharma has reported Assets Average for 8 years, with the latest figure at $36.9 million in Q4 2025.
- Quarterly Assets Average fell 4.08% year-over-year to $36.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $36.9 million (down 4.08% YoY) and the FY2025 annual result came in at $37.2 million, down 20.61% from the prior year.
- Assets Average rose to $36.9 million in Q4 2025 per CUE's latest filing, from $36.2 million in the prior quarter.
- Over five years, Assets Average peaked at $94.1 million in Q1 2021 and troughed at $27.2 million in Q1 2025.
- A 5-year average of $65.4 million and a median of $74.2 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2021 and 2025: Assets Average surged 42.34% in 2021, then plunged 52.85% in 2025.
- Over 5 years, Assets Average stood at $81.1 million in 2021, then gained by 3.27% to $83.8 million in 2022, then fell by 22.18% to $65.2 million in 2023, then plunged by 40.96% to $38.5 million in 2024, then fell by 4.08% to $36.9 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $36.9 million, $36.2 million, and $31.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | 36.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 36.93 Mn |
| Sep 30, 2025 | 36.18 Mn |
| Jun 30, 2025 | 31.48 Mn |
| Mar 31, 2025 | 27.22 Mn |
| Dec 31, 2024 | 38.50 Mn |
| Sep 30, 2024 | 43.57 Mn |
| Jun 30, 2024 | 48.14 Mn |
| Mar 31, 2024 | 57.74 Mn |
| Dec 31, 2023 | 65.21 Mn |
| Sep 30, 2023 | 71.03 Mn |
| Jun 30, 2023 | 77.42 Mn |
| Mar 31, 2023 | 86.48 Mn |
| Dec 31, 2022 | 83.79 Mn |
| Sep 30, 2022 | 80.52 Mn |
| Jun 30, 2022 | 87.73 Mn |
| Mar 31, 2022 | 87.05 Mn |
| Dec 31, 2021 | 81.14 Mn |
| Sep 30, 2021 | 84.27 Mn |
| Jun 30, 2021 | 89.20 Mn |
| Mar 31, 2021 | 94.13 Mn |